New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

(2019) Connie B. Newman et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease

(2019) Shuaib M. Abdullah et al.   CIRCULATION

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry

(2019) Kornelia Kotseva et al.   European Journal of Preventive Cardiology

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

(2019) Jane Armitage et al.   LANCET

Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease

(2019) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

(2018) Christie M. Ballantyne et al.   ATHEROSCLEROSIS

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

(2018) François Mach et al.   EUROPEAN HEART JOURNAL

Pathological phenotypes of LDL particles

(2018) Ulrich Laufs et al.   EUROPEAN HEART JOURNAL

Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths

(2018) Maija Ruuth et al.   EUROPEAN HEART JOURNAL

Cardiovascular disease: The rise of the genetic risk score

(2018) Joshua W. Knowles et al.   PLOS MEDICINE

Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

(2018) Amit V. Khera et al.   NATURE GENETICS

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

(2018) Scott M. Grundy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults

(2018) Michael Inouye et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk

(2018) Julius Katzmann et al.   Patient Preference and Adherence

Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease

(2018) Julia Dittrich et al.   ATHEROSCLEROSIS

Vaccination to prevent atherosclerotic cardiovascular diseases

(2017) Ulrich Laufs et al.   EUROPEAN HEART JOURNAL

Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena

(2017) Sarah Costantino et al.   EUROPEAN HEART JOURNAL

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

(2017) Ulf Landmesser et al.   EUROPEAN HEART JOURNAL

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

(2017) Brian A Ference et al.   EUROPEAN HEART JOURNAL

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

(2017) Christine Landlinger et al.   EUROPEAN HEART JOURNAL

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk

(2017) Brian A. Ference et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Individualized lipid-lowering therapy to further reduce residual cardiovascular risk

(2017) Oliver Weingärtner et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

(2017) Robert P Giugliano et al.   LANCET

Cognitive Function in a Randomized Trial of Evolocumab

(2017) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol

(2017) Robert P. Giugliano et al.   JAMA Cardiology

Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey

(2016) Ž. Reiner et al.   ATHEROSCLEROSIS

Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin TherapyCLINICAL PERSPECTIVE

(2016) Ian Ford et al.   CIRCULATION

Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk

(2016) Ulrich Laufs et al.   Clinical Research in Cardiology

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

(2016) Ozlem Bilen et al.   Current Atherosclerosis Reports

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes

(2016) Luca A. Lotta et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease

(2016) Amit V. Khera et al.   NEW ENGLAND JOURNAL OF MEDICINE

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

(2016) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment

(2016) Roelof AJ Smit et al.   PHARMACOGENOMICS

Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease

(2015) A. M. Navar-Boggan et al.   CIRCULATION

Mendelian randomization studies

(2015) Brian A. Ference   CURRENT OPINION IN LIPIDOLOGY

Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both

(2015) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

(2015) Jessica L Mega et al.   LANCET

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials

(2015)   LANCET

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory

(2015) Chris J. Packard et al.   VASCULAR PHARMACOLOGY

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries

(2015) Kornelia Kotseva et al.   European Journal of Preventive Cardiology

Mendelian randomization: genetic anchors for causal inference in epidemiological studies

(2014) G. Davey Smith et al.   HUMAN MOLECULAR GENETICS

Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins

(2014) Iris Postmus et al.   Nature Communications

Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease

(2013) Michael Böhm et al.   AMERICAN HEART JOURNAL

Nonoptimal Lipids Commonly Present in Young Adults and Coronary Calcium Later in Life: The CARDIA (Coronary Artery Risk Development in Young Adults) Study

(2013) Mark J. Pletcher   ANNALS OF INTERNAL MEDICINE

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy

(2013) Peter Libby   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin‐Treated Subjects From 3 Data Sources: A Retrospective Analysis

(2013) Peter H. Jones et al.   Journal of the American Heart Association

Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials

(2012) Jennifer G. Robinson et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease

(2012) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Strategies to improve drug adherence

(2010) U. Laufs et al.   EUROPEAN HEART JOURNAL

Continuation of Statin Treatment and All-Cause Mortality

(2009) Varda Shalev et al.   ARCHIVES OF INTERNAL MEDICINE

Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents

(2009) Ajay K. Gupta et al.   HYPERTENSION